The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing Enterobacterales infections: a systematic review and meta-analysis
JAC-Antimicrobial Resistance · 07.01.2026 · 8 (1)
DOI: 10.1093/jacamr/dlaf238 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 07.01.2026. Verfasst von Ashley Li-Ann Foo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Medical Research Council, NMRC Clinician Scientist Individual Research Grant, NMRC Clinician Scientist Award.
Abstract (Originalsprache)
Objectives
To assess the impact of ceftazidime-avibactam on 30-day all-cause mortality in patients with OXA-48 producing Enterobacterales infections, in comparison to alternative best available therapy (BAT).
Methods
Systematic review and meta-analysis of observational studies comparing 30-day mortality outcomes in patients infected with OXA-48 producing Enterobacterales, treated with ceftazidime-avibactam versus BAT. Clinical success (improvement in symptoms/signs of infection) at the end of therapy was assessed as a secondary outcome. We searched six electronic databases (PubMed, EMBASE, CINAHL, Scopus, CENTRAL, Web of Science). Two independent authors carried out the title and abstract review, full text review and data extraction.
Results
We included five observational studies for our final analysis. None of the studies had a low risk of bias. We calculated effect estimates and used a random effects meta-analysis to generate pooled estimates. Our primary analysis found that ceftazidime-avibactam was associated with lower 30-day mortality (OR 0.46, 56/249, 22.5% versus 97/265, 36.6%, 95% CI 0.29–0.71). Our secondary analysis for the outcome of clinical success was assessable for three studies and also showed benefit (OR 3.6, 95% CI 1.85–6.9). Adjusted analyses could not be performed.
Conclusions
Ceftazidime-avibactam seemed to be associated with a lower 30-day mortality and more favourable clinical outcomes compared with BAT in the treatment of OXA-48 Enterobacterales infections. Although these findings provide tentative support for current ESCMID/IDSA antibiotic use guidelines for the use of ceftazidime-avibactam for OXA-48 Enterobacterales infections, further high-quality research is required to confirm this and evaluate its role in relation with other emerging novel therapies.
Autor:innen und Institutionen
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Department of Infectious Diseases, National Centre for Infectious Diseases, Singapore.
- Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore.
- Communicable Disease Agency Research Group, Communicable Diseases Agency, Singapore.
Förderung
- National Medical Research Council
- NMRC Clinician Scientist Individual Research Grant
- NMRC Clinician Scientist Award
Zitieren
APA
Foo, A. L., Young, B., Ng, O. T., & Vasoo, S. (2026). The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing Enterobacterales infections: a systematic review and meta-analysis. JAC-Antimicrobial Resistance, 8(1). https://doi.org/10.1093/jacamr/dlaf238
Vancouver
Foo AL, Young B, Ng OT, Vasoo S. The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing Enterobacterales infections: a systematic review and meta-analysis. JAC-Antimicrobial Resistance. 2026;8(1). doi:10.1093/jacamr/dlaf238
BibTeX
@article{Foo2026,
author = {Foo, Ashley Li-Ann and Young, Barnaby and Ng, Oon Tek and Vasoo, Shawn},
title = {The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing Enterobacterales infections: a systematic review and meta-analysis},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/jacamr/dlaf238}
}
EUVIMED